keyword
MENU ▼
Read by QxMD icon Read
search

Metastasis bone tumor

keyword
https://www.readbyqxmd.com/read/29776413/the-cxcr4-antagonist-plerixafor-amd3100-promotes-proliferation-of-ewing-sarcoma-cell-lines-in-vitro-and-activates-receptor-tyrosine-kinase-signaling
#1
Philipp Berning, Christiane Schaefer, Dagmar Clemens, Eberhard Korsching, Uta Dirksen, Jenny Potratz
BACKGROUND: The CXCR4 receptor antagonist plerixafor (AMD3100) is raising interest as an anti-cancer agent that disrupts the CXCL12-CXCR4 chemokine - receptor interaction between neoplastic cells and their microenvironment in tumor progression and metastasis. Here, we investigated plerixafor for anti-cancer activity in Ewing sarcoma, a rare and aggressive cancer of bone and soft tissues. METHODS: We used a variety of methods such as cell viability and migration assays, flow cytometry, phospho-tyrosine arrays and western blotting to determine plerixafor effects on five characterized Ewing sarcoma cell lines and a low-passage culture in vitro...
May 18, 2018: Cell Communication and Signaling: CCS
https://www.readbyqxmd.com/read/29774766/negative-prognostic-factors-and-resulting-clinical-outcome-in-patients-with-metastatic-renal-cell-carcinoma-included-in-the-italian-nivolumab-expanded-access-program
#2
Sergio Bracarda, Luca Galli, Marco Maruzzo, Giovanni Lo Re, Sebastiano Buti, Adolfo Favaretto, Francesco Di Costanzo, Cosimo Sacco, Marco Merlano, Claudia Mucciarini, Elena Zafarana, Sante Romito, Antonio Maestri, Carmelo G Giorgio, Maria T Ionta, Daniele Turci, Ugo De Giorgi, Giuseppe Procopio, Enrico Cortesi, Diana Giannarelli, Camillo Porta
AIM: We report the outcomes observed with nivolumab in metastatic renal cell carcinoma patients with poor prognostic features enrolled in the Italian expanded access program. PATIENTS & METHODS: Nivolumab was available for patients who relapsed after at least one prior systemic treatment in the advanced or metastatic setting. RESULTS: Of 389 patients, 32 (8%) had brain metastasis, 129 (33%) had liver and 193 (50%) had bone metastasis. These subpopulations achieved a disease control rate of 53, 45 and 47%, respectively...
May 18, 2018: Future Oncology
https://www.readbyqxmd.com/read/29774441/bst2-promotes-cell-proliferation-migration-and-induces-nf-%C3%AE%C2%BAb-activation-in-gastric-cancer
#3
Weiyu Liu, Yong Cao, Yadi Guan, Changqing Zheng
OBJECTIVES: To investigate the functional roles of bone marrow stromal cell antigen 2 (BST2) in gastric cancer (GC) cells and its implications in the development of GC patients. RESULTS: BST2 was frequently overexpressed in GC tissues compared with the adjacent non-tumorous tissues, and high BST2 expression was correlated with tumor stage and lymphatic metastasis. Furthermore, in vitro experiments demonstrated that knockdown of BST2 by siRNA inhibited cell proliferation, induced apoptosis and repressed cell motility in GC cells...
May 17, 2018: Biotechnology Letters
https://www.readbyqxmd.com/read/29772510/dkk1-and-kremen-expression-predicts-the-osteoblastic-response-to-bone-metastasis
#4
Katrina L Clines, Gregory A Clines
Bone metastasis is a complication of advanced breast and prostate cancer. Tumor-secreted Dickkopf homolog 1 (DKK1), an inhibitor of canonical Wnt signaling and osteoblast differentiation, was proposed to regulate the osteoblastic response to metastatic cancer in bone. The objectives of this study were to compare DKK1 expression with the in vivo osteoblastic response in a panel of breast and prostate cancer cell lines, and to discover mechanisms that regulate cancer DKK1 expression. DKK1 expression was highest in MDA-MB-231 and PC3 cells that produce osteolytic lesions, and hence a suppressed osteoblastic response, in animal models of bone metastasis...
May 14, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29770232/long-term-follow-up-of-adamantinoma-of-the-tibia-complicated-by-metastases-and-a-second-unrelated-primary-cancer-a-case-report-and-literature-review
#5
Brendan R Southam, Alvin H Crawford, David A Billmire, James Geller, Daniel Von Allmen, Adam P Schumaier, Sara Szabo
Adamantinoma is a rare, low-grade malignant tumor of the bone which grows slowly and typically occurs in the diaphysis of long bones, particularly in the tibia. Adamantinomas have the potential for local recurrence and may metastasize to the lungs, lymph nodes, or bone. We report a case of a 14-year-old female with a tibial adamantinoma who underwent wide resection with limb salvage and has subsequently been followed up for 18 years. The patient went on to have both a local soft tissue recurrence 5 years after the resection and metastases to both an inguinal lymph node and the right lower lobe of the lung 8 years after that recurrence, all of which have been treated successfully with marginal resections...
2018: Case Reports in Orthopedics
https://www.readbyqxmd.com/read/29769196/an-in-vivo-screen-identifies-pygo2-as-a-driver-for-metastatic-prostate-cancer
#6
Xin Lu, Xiaolu Pan, Chang-Jiun Wu, Di Zhao, Shan Feng, Yong Zang, Rumi Lee, Sunada Khadka, Samirkumar B Amin, Eun-Jung Jin, Xiaoying Shang, Pingna Deng, Yanting Luo, William R Morgenlander, Jacqueline Weinrich, Xuemin Lu, Shan Jiang, Qing Chang, Nora M Navone, Patricia Troncoso, Ronald A DePinho, Y Alan Wang
Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy number aberrations, yet the identity of functional drivers resident in many amplicons remain elusive. Here, we implemented a functional genomics approach to identify new oncogenes involved in prostate cancer progression. Through integrated analyses of focal amplicons in large prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen...
May 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29769195/osteocyte-driven-downregulation-of-snail-restrains-effects-of-drd2-inhibitors-on-mammary-tumor-cells
#7
Shengzhi Liu, Yao Fan, Andy Chen, Aydin Jalali, Kazumasa Minami, Kazuhiko Ogawa, Harikrishna Nakshatri, Bai-Yan Li, Hiroki Yokota
While bone is a frequent target of breast cancer-associated metastasis, little is known about the effects of tumor-bone interactions on the efficacy of tumor-suppressing agents. Here we examined the effect of two FDA-approved dopamine modulators, Fluphenazine (FP) and Trifluoperazine (TFP), on mammary tumor cells, osteoclasts, osteoblasts, and osteocytes. These agents suppressed proliferation and migration of mammary tumor cells chiefly by antagonizing dopamine receptor D2 and reduced bone resorption by downregulating nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1)...
May 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29769179/rna-profiles-of-circulating-tumor-cells-and-extracellular-vesicles-for-therapy-stratification-of-metastatic-breast-cancer-patients
#8
Corinna Keup, Pawel Mach, Bahriye Aktas, Mitra Tewes, Hans-Christian Kolberg, Siegfried Hauch, Markus Sprenger-Haussels, Rainer Kimmig, Sabine Kasimir-Bauer
BACKGROUND: Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) to estimate their utility in therapy management. METHODS: Blood was collected from 35 hormone receptor-positive/HER2-negative patients with MBC at the time of disease progression and at 2 consecutive staging time points...
May 16, 2018: Clinical Chemistry
https://www.readbyqxmd.com/read/29766567/melatonin-attenuates-osteosarcoma-cell-invasion-by-suppression-of-c-c-motif-chemokine-ligand-24-through-inhibition-of-the-c-jun-n-terminal-kinase-pathway
#9
Ko-Hsiu Lu, Shih-Chi Su, Chiao-Wen Lin, Yi-Hsien Hsieh, Ya-Chiu Lin, Ming-Hsien Chien, Russel J Reiter, Shun-Fa Yang
Osteosarcoma, with its high metastatic potential, is the most prevalent malignant bone tumor in children and adolescents. Melatonin possesses multiple tumor-suppressing properties for a myriad of tumors, but little is known about the effects of melatonin on osteosarcoma metastasis. In this study, we demonstrated that melatonin elicited very low cytotoxicity and significantly inhibited cellular motility, migration, and invasion in human osteosarcoma U2OS and HOS cells. Moreover, using RNA sequencing technology, we revealed that melatonin repressed C-C motif chemokine ligand 24 (CCL24) gene expression in U2OS cells...
May 16, 2018: Journal of Pineal Research
https://www.readbyqxmd.com/read/29765511/immunohistochemical-analysis-of-rhamm-expression-in-normal-and-neoplastic-human-tissues-a-cell-cycle-protein-with-distinctive-expression-in-mitotic-cells-and-testicular-germ-cells
#10
Yao-Tseng Chen, Zhengming Chen, Yi-Chieh Nancy Du
Expression of Receptor for Hyaluronic Acid Mediated Motility (RHAMM) increases cellular motility and RHAMM overexpression promotes invasive phenotype and metastasis of cancer cells. RHAMM has been suggested as a biomarker for poor prognosis in several tumor types, including lung, breast, colorectal, gastric, pancreatic ductal, and ovarian cancers. RNA studies showed restricted RHAMM expression in normal tissues, but its protein expression data in tissues were limited. In light of its potential as a prognostic marker and a therapeutic target, we performed immunohistochemical analysis to systematically characterize RHAMM expression in normal and neoplastic human tissues...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29761076/synchronous-bone-metastasis-from-multiple-myeloma-and-prostate-adenocarcinoma-as-initial-presentation-of-coexistent-malignancies
#11
Diego Andres Adrianzen Herrera, Shlomit Goldberg-Stein, Alexander Sankin, Judy Sarungbam, Janaki Sharma, Benjamin A Gartrell
The radiographic appearance of bone metastases is usually determined by tumor histology and can be osteolytic, osteoblastic, or mixed. We present a patient with coexistent bone metastasis from multiple myeloma and prostate adenocarcinoma who exhibited synchronous bone involvement of both histologies within the same bone lesion, a rare phenomenon that has not been previously reported and led to atypical radiographic findings. The radiograph of a 71-year-old man with thigh swelling and pain demonstrated a lytic femoral lesion...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29759731/intrafibrillar-bone-mimetic-collagen-mineralization-regulates-breast-cancer-cell-adhesion-and-migration
#12
Siyoung Choi, Jens Friedrichs, Young Hye Song, Carsten Werner, Lara A Estroff, Claudia Fischbach
Bone metastasis is a leading cause of death in patients with breast cancer, but the underlying mechanisms are poorly understood. While much work focuses on the molecular and cellular events that drive breast cancer bone metastasis, it is mostly unclear what role bone extracellular matrix (ECM) properties play in this process. Bone ECM primarily consists of mineralized collagen fibrils, which are composed of non-stoichiometric carbonated apatite (HA) and collagen type I. Reduced bone mineral content is epidemiologically linked with increased risk of bone metastasis...
May 7, 2018: Biomaterials
https://www.readbyqxmd.com/read/29755127/a-novel-long-non-coding-rna-linc-znf469-3-promotes-lung-metastasis-through-mir-574-5p-zeb1-axis-in-triple-negative-breast-cancer
#13
Po-Shun Wang, Cheng-Han Chou, Cheng-Han Lin, Yun-Chin Yao, Hui-Chuan Cheng, Hao-Yi Li, Yu-Chung Chuang, Chia-Ning Yang, Luo-Ping Ger, Yu-Chia Chen, Forn-Chia Lin, Tang-Long Shen, Michael Hsiao, Pei-Jung Lu
Triple-negative breast cancer (TNBC) patients usually lead to poor prognosis and survival because of metastasis. The major sites for TNBC metastasis include the lungs, brain, liver, and bone. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts longer than 200 nucleotides and have been reported as important regulators in BC metastasis. However, the underlying mechanisms for lncRNAs regulating TNBC metastasis are not fully understood. Here we found that linc-ZNF469-3 was highly expressed in lung-metastatic LM2-4175 TNBC cells and overexpression of linc-ZNF469-3 enhanced invasion ability and stemness properties in vitro and lung metastasis in vivo...
May 14, 2018: Oncogene
https://www.readbyqxmd.com/read/29751634/rho-a-regulates-epidermal-growth-factor-induced-human-osteosarcoma-mg63-cell-migration
#14
Jinyang Wang, Lei Zhang, Rongmei Qu, Lin Zhang, Wenhua Huang
Osteosarcoma, the most common primary bone tumor, occurs most frequently in children and adolescents and has a 5-year survival rate, which is unsatisfactory. As epidermal growth factor receptor (EGFR) positively correlates with TNM (tumor-node-metastasis) stage in osteosarcoma, EGFR may play an important role in its progression. The purpose of this study was to explore potential mechanisms underlying this correlation. We found that EGF promotes MG63 cell migration and invasion as well as stress fiber formation via Rho A activation and that these effects can be reversed by inhibiting Rho A expression...
May 11, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29750708/endometrioid-adenocarcinoma-with-solitary-metastasis-to-the-appendix-mimicking-primary-appendiceal-adenocarcinoma-a-case-report-and-literature-review
#15
Qiujie Ma, Jianshe Wu
Metastatic tumors of the appendix are rare. Endometrial cancer tends to metastasize by directly invading neighboring structures; the lung, liver, bones, and brain are common sites of distant metastasis. Herein, we present a case of a solitary endometrial metastatic tumor in the appendiceal mucosa without serosal involvement that mimicked a primary adenocarcinoma of the appendix. The patient who had undergone a radical hysterectomy for an endometrioid adenocarcinoma 3 years earlier presented to the hospital with a history of persistent right-lower abdominal pain...
May 10, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29748233/prospective-study-of-serial-18-f-fdg-pet-and-18-f-fluoride-18-f-naf-pet-to-predict-time-to-skeletal-related-events-time-to-progression-and-survival-in-patients-with-bone-dominant-metastatic-breast-cancer
#16
Lanell M Peterson, Janet O'Sullivan, Qian Vicky Wu, Alena Novakova-Jiresova, Isaac Jenkins, Jean H Lee, Andrew Shields, Susan Montgomery, Hannah M Linden, Julie R Gralow, Vijayakrishna K Gadi, Mark Muzi, Paul E Kinahan, David A Mankoff, Jennifer M Specht
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18 F-FDG PET was predictive of time to skeletal related events (tSRE) and time-to-progression (TTP). 18 F-NaF PET improves bone metastasis detection compared to bone scans. We prospectively tested 18 F-FDG PET and 18 F-NaF PET to predict tSRE, TTP, and overall survival (OS) in patients with bone-dominant metastatic breast cancer (BD MBC). Methods: Patients with BD MBC were imaged with 18 F-FDG PET and 18 F-NaF PET prior to starting new therapy (scan1) and again at a range of times centered around approximately 4 months later (scan2)...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29748100/impact-of-magnetic-resonance-imaging-on-gross-tumor-volume-delineation-in-non-spine-bony-metastasis-treated-with-stereotactic-body-radiation-therapy
#17
Srinivas Raman, Lee Chin, Darby Erler, Eshetu G Atenafu, Patrick Cheung, William Chu, Hans Chung, Andrew Loblaw, Ian Poon, Joel Rubenstein, Hany Soliman, Arjun Sahgal, Chia-Lin Tseng
PURPOSE: This study investigates the inter-observer variability of contouring non-spine bone metastases using the planning CT alone vs. the addition of MRI T1 and T2 imaging sequences. METHODS AND MATERIALS: 10 cases of non-spine bone metastases treated with SBRT at our institution were selected. The gross tumor volume (GTV) for each case was delineated by six SBRT radiation oncologists (RO) and one diagnostic radiologist (DR) on the treatment planning CT. After a minimum of three months, each case was re-contoured on the CT fused with a MRI T1 sequence followed by a MRI T2 sequence...
March 17, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29746867/mir-26a-5p-potentiates-metastasis-of-human-lung-cancer-cells-by-regulating-itg%C3%AE-8-jak2-stat3-axis
#18
Qianqian Song, Boning Liu, Xueqin Li, Qicheng Zhang, Limin Cao, Meilin Xu, Zhaowei Meng, Xiang Wu, Ke Xu
Most lung cancer patients die of metastasis. Recent studies have indicated that dysregulated microRNAs (miRNAs) are involved not only in tumorigenesis, but also in metastasis. In the present study, we found that over-expression of miR-26a-5p potentiated the migration and invasion of lung cancer cells evidenced by wound healing assay and transwell assay, and metastasis-related genes MMP-9 and CD44 were up-regulated. We identified integrin-beta8 (ITGβ8) as a novel target of miR-26a, and ITGβ8 expression was negatively correlated with miR-26a-5p expression in lung cancer specimens...
May 7, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29746513/role-of-18f-fdg-pet-ct-in-patients-without-known-primary-malignancy-with-skeletal-lesions-suspicious-for-cancer-metastasis
#19
Soo Bin Park, Jung Mi Park, Seung Hwan Moon, Young Seok Cho, Jong-Mu Sun, Byung-Tae Kim, Kyung-Han Lee
BACKGROUND: When subjects without a known malignancy present with suspicious skeletal lesions, differential diagnosis and primary cancer identification is important. Here, we investigated the role of FDG PET/CT in this clinical situation. METHODS: We enrolled 103 patients with no known malignancies who were referred for FDG PET/CT because of bone lesions that were suspicious for cancer metastasis. Each extra-skeletal FDG lesion was categorized as consistent with primary cancer or with metastasis based on the distribution and pattern of all abnormal lesions in the individual...
2018: PloS One
https://www.readbyqxmd.com/read/29745092/therapeutic-benefits-of-neoadjuvant-and-post-operative-denosumab-on-sacral-giant-cell-tumor-a-retrospective-cohort-study-of-30-cases
#20
Zhongyan Chen, Yi Yang, Wei Guo, Rongli Yang, Xiaodong Tang, Taiqiang Yan, Tao Ji, Lu Xie, Jie Xu, Jun Wang
PURPOSE: Denosumab, a new monoclonal antibody that inhibits receptor activator for nuclear factor Kβ ligand (RANKL), has recently been approved by FDA for the treatment of aggressive giant cell tumor of bone (GCTB). So we initiated this study to evaluate the clinical benifits of denosumab used preoperatively or postoperatively. METHODS: Patients diagnosed with classic sacral GCT without metastasis were included in this study. Patients were assigned into 3 groups according to the use of denosumab: control group 1, post-operative group 2 and neoadjuvant group 3...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
56041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"